Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dzwonczyk

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Cardiovascular Research|January 1, 1995
Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heartE O Weselcouch, A J Baird, P G Sleph, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotectionG J Grover, P G Sleph, S Dzwonczyk, et al.
Circulation Research|October 1, 1991
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoateJ R McCullough, D E Normandin, M L Conder, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanismG J Grover, A J D'Alonzo, P G Sleph, et al.
Journal of Cardiovascular Pharmacology|August 1, 1995
Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946]G J Grover, S Dzwonczyk, D M McMullen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channelC A Sargent, P G Sleph, S Dzwonczyk, et al.
Cardiovascular Research|February 1, 1996
Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat heartsC A Sargent, M W Wilde, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotidesG J Grover, J Newburger, P G Sleph, et al.
Pharmacology|February 1, 1996
Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat heartsA J D'Alonzo, G J Grover, R B Darbenzio, et al.
Journal of Medicinal Chemistry|May 26, 1995
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ringK S Atwal, G J Grover, F N Ferrara, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cardiovascular Research|January 1, 1995
Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heartE O Weselcouch, A J Baird, P G Sleph, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotectionG J Grover, P G Sleph, S Dzwonczyk, et al.
Circulation Research|October 1, 1991
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoateJ R McCullough, D E Normandin, M L Conder, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanismG J Grover, A J D'Alonzo, P G Sleph, et al.
Journal of Cardiovascular Pharmacology|August 1, 1995
Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946]G J Grover, S Dzwonczyk, D M McMullen, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channelC A Sargent, P G Sleph, S Dzwonczyk, et al.
Cardiovascular Research|February 1, 1996
Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat heartsC A Sargent, M W Wilde, S Dzwonczyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotidesG J Grover, J Newburger, P G Sleph, et al.
Pharmacology|February 1, 1996
Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat heartsA J D'Alonzo, G J Grover, R B Darbenzio, et al.
Journal of Medicinal Chemistry|May 26, 1995
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ringK S Atwal, G J Grover, F N Ferrara, et al.
Pageof 4